Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Johns Hopkins Medicine researchers say they have found that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision.
New research from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine is shining a light on whether vision screenings for older drivers identify those who are likely to have motor vehicle collisions in the next few years.
The AREDS2 formula not only reduces risk of lung cancer due to beta-carotene, but is also more effective at reducing risk of AMD progression, compared to the original formula.
A 28-patient phase 1 gene therapy clinical trial for the degenerative retinal disease Leber hereditary optic neuropathy (LHON) found no significant safety concerns; however, treatment failed to improve or slow vision loss, with even the highest dose.
Researchers have identified distinct differences among the cells comprising a tissue in the retina that is vital to human visual perception. The scientists from the National Eye Institute (NEI) discovered five subpopulations of retinal pigment epithelium.
The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.
A Stanford scientist and his colleagues show that patients fitted with a chip in their eye are able to integrate what the chip “sees” with objects their natural peripheral vision detects.
National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.
